Back

Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients and a pulmonary artery pressure sensor: does left ventricular ejection fraction matter?

12 May 2024 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 13 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Evelyn Santiago-Vacas

University Hospital Germans Trias and Pujol de Badalona, Badalona (Spain)

4 More presentations in this session

Presentation thumbnail
Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction
Doctor C. Carvalho (Viana do Castelo, PT)
Abstract Slides Video
Presentation thumbnail
Impact of the guideline-directed medical therapy on the eligibility of patients for mitral valve transcatheter edge-to-edge repair in HFrEF
Doctor B. Muk (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Beyond assumptions: NT-proBNP rise and diuretic strategies in HFrEF therapy up-titration
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Initial 6-hour injectable diuretic therapy on 24-month outcomes in acute heart failure patients
Doctor A. Singh (Manipal, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 13

The Event

Event poster

Heart Failure 2024

12 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients with a pulmonary artery pressure sensor.
thumbnail
Congress Presentation
Impact of sodium-glucose co-transporter 2 inhibition on right ventricular function and pulmonary artery systolic pressure across heart failure phenotypes: a meta-analytic approach
thumbnail
Congress Presentation
SGLT2i downregulate the activin/inhibin and miR-1306-5p signaling pathways in patients with HFrEF and associated pulmonary hypertension: a prospective intervention study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources